Enanta Pharmaceuticals Inc (ENTA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Enanta Pharmaceuticals Inc stock (ENTA) is currently trading at $12.08. Enanta Pharmaceuticals Inc PS ratio (Price-to-Sales) is 5.42. Analyst consensus price target for ENTA is $20.50. WallStSmart rates ENTA as Sell.
- ENTA PE ratio analysis and historical PE chart
- ENTA PS ratio (Price-to-Sales) history and trend
- ENTA intrinsic value — DCF, Graham Number, EPV models
- ENTA stock price prediction 2025 2026 2027 2028 2029 2030
- ENTA fair value vs current price
- ENTA insider transactions and insider buying
- Is ENTA undervalued or overvalued?
- Enanta Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- ENTA Piotroski F-Score and Altman Z-Score
- ENTA analyst price target and Smart Rating
Enanta Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Enanta Pharmaceuticals Inc (ENTA) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Enanta Pharmaceuticals Inc (ENTA) Key Strengths (1)
91.53% of shares held by major funds and institutions
Supporting Valuation Data
Enanta Pharmaceuticals Inc (ENTA) Areas to Watch (8)
Company is destroying shareholder value
Losing money on operations
Earnings declining -66.20%, profits shrinking
Company is losing money with a negative profit margin
Premium valuation at 5.4x annual revenue
Modest revenue growth at 9.80%
Small-cap company with higher risk but more growth potential
Fairly priced relative to book value
Supporting Valuation Data
Enanta Pharmaceuticals Inc (ENTA) Detailed Analysis Report
Overall Assessment
This company scores 28/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 2.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (5.42), Price/Book (2.87) suggest expensive pricing. Growth concerns include Revenue Growth at 9.80%, EPS Growth at -66.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -60.00%, Operating Margin at -60.50%, Profit Margin at -106.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -60.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 9.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ENTA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ENTA's Price-to-Sales ratio of 5.42x trades at a deep discount to its historical average of 13.23x (21th percentile). The current valuation is 87% below its historical high of 40.66x set in Jun 2014, and 147% above its historical low of 2.19x in Jan 2025. Over the past 12 months, the PS ratio has expanded from ~2.4x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Enanta Pharmaceuticals Inc (ENTA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Enanta Pharmaceuticals Inc is in a turnaround phase, with management focused on restoring profitability. Revenue reached 67M with 10% growth year-over-year. The company is currently unprofitable, posting a -106.8% profit margin.
Key Findings
Spending 31% of revenue (21M) on R&D, reinforcing its commitment to innovation and future growth.
The company is unprofitable with a -106.8% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -12M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Enanta Pharmaceuticals Inc.
Bottom Line
Enanta Pharmaceuticals Inc is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Enanta Pharmaceuticals Inc(ENTA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.